Characterization of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy

Prostate

Volumn 67, Issue 4, 2007, Pages 389-395

  Carlsson, Björn ^a   Forsberg, Ole ^a   Bengtsson, Mats ^a   Tötterman, Thomas H ^a   Essand, Magnus ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cell line; HLA; Immunotherapy; Tumor associated antigen

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; COMPLEMENTARY DNA; GENOMIC DNA; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL IMMORTALIZATION; CELL STRAIN MCF 7; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HLA TYPING; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ADENOCARCINOMA; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, CD86; BREAST NEOPLASMS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; GENE EXPRESSION; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERCELLULAR ADHESION MOLECULE-1; MALE; PROSTATIC NEOPLASMS; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 33847359519     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20498     Document Type: Article

References (20)

1. Essand M. Gene therapy and immunotherapy of prostate cancer: Adenoviral-based strategies. Acta Oncol 2005;44(6):610-627.
2. Sauter ER, Babb J, Daly M, Engstrom PF, Ehya H, Malick J, Diamandis E. Prostate-specific antigen production in the female breast: Association with progesterone. Cancer Epidemiol Biomarkers Prev 1998;7(4):315-320.
3. Sauter ER, Lininger J, Magklara A, Hewett JE, Diamandis EP. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. Int J Cancer 2004;108(4):588-591.
4. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43(4):1809-1818.
5. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17(1):16-23.
6. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978;21(3):274-281.
7. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 1995;31(1):14-24.
8. van Weerden WM, de Ridder CM, Verdaasdonk CL, Romijn JC, van der Kwast TH, Schroder FH, van Steenbrugge GJ. Development of seven new human prostate tumor xenograf t models and their histopathological characterization. Am J Pathol 1996;149(3):1055-1062.
9. Lang SH, Stower M, Maitland NJ. In vitro modelling of epithelial and stromal interactions in non-malignant and malignant prostates. Br J Cancer 2000;82(4):990-997.
10. Keydar I, Chen L, Karby S, Weiss FR, Delarea J, Radu M, Chaitcik S, Brenner HJ. Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer 1979;15(5):659-670.
11. Brooks SC, Locke ER, Soule HD. Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem 1973;248(17):6251-6253.
12. Bengtsson M, Danielsson F, Jansson IE, Jidell E, Johansson U. Two new HLA Cw* alleles, Cw*0105 and Cw*1405, detected by sequence based typing. Tissue Antigens 2002;59(3):226-228.
13. Carlsson B, Totterman TH, Essand M. Generation of cytolytic T lymphocytes specific for the prostate and breast tissue antigen TARP. Prostate 2004;61(2):161-170.
14. Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 2002;62(20):5807-5812.
15. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, Simons JW. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995;87(4):280-285.
16. Anikeeva N, Somersalo K, Sims TN, Thomas VK, Dustin ML, Sykulev Y. Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes. Proc Natl Acad Sci USA 2005;102(18):6437-6442.
17. Errington F, Bateman A, Kottke T, Thompson J, Harrington K, Merrick A, Hatfield P, Selby P, Vile R, Melcher A. Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. Clin Cancer Res 2006;12(4):1333-1341.
18. Ward S, Casey D, Labarthe MC, Whelan M, Dalgleish A, Pandha H, Todryk S. Immunotherapeutic potential of whole tumour cells. Cancer Immunol Immunother 2002;51(7):351-357.
19. Michael A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J, Chakraborty P, Leader D, Whelan M, Pandha H. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005;11(12):4469-4478.
20. Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, Hammerstad H, Waehre H, Raabe N, Gaudernack G. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 2005;93(7):749-756.